Key Insights:
- Market Growth: Understand the significant growth trajectory of the Crohn`s Disease End-Use segment, which is expected to reach US$19 Billion by 2030 with a CAGR of 4.3%. The Ulcerative Colitis End-Use segment is also set to grow at 4.6% CAGR over the next 8 years.
- Regional Analysis: Gain insights into the U.S. market, estimated at $18.4 Billion in 2023, and China, forecasted to grow at an impressive 6.9% CAGR to reach $22.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Gastrointestinal Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Gastrointestinal Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Gastrointestinal Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as AbbVie, Inc., Alfa Wassermann, Inc., Allergan PLC, and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 44 Featured):
- AbbVie, Inc.
- Alfa Wassermann, Inc.
- Allergan PLC
- Amgen, Inc.
- Anterogen Co., Ltd.
- Ardelyx, Inc.
- Astellas Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biogen, Inc.
- Celgene Corporation
- Cosmo Pharmaceuticals NV
- Drais Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Enlivex Therapeutics ltd.
- F. Hoffmann-La Roche AG
- Ferring Pharmaceuticals, Inc.
- FF Pharma
- Galapagos NV
- Gilead Sciences, Inc.
- GlaxoSmithKline, Inc.
- Hutchison MediPharma Limited
- Immune Pharmaceuticals, Inc.
- InDex Pharmaceuticals Holding AB
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Lexicon Pharmaceuticals, Inc.
- Lipid Therapeutics GmbH
- Meda AB
- Merck & Co., Inc.
- Mesoblast Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Mochida Pharmaceutical Co., Ltd.
- Morphotek, Inc.
- Neovacs S.A.
- Nestle SA
- Norgine BV
- Novartis AG
- Pfizer, Inc.
- Procter & Gamble Company, The
- Qu Biologics Inc.
- RedHill Biopharma Ltd.
- Sterna Biologicals GmbH & Co. KG
- Synthetic Biologics, Inc.
- Takeda Pharmaceutical Co., Ltd.
- TiGenix NV
- Tillotts Pharma AG
- TopiVert Ltd.
- UCB SA
MarketGlass Platform
Our reports are enhanced by the MarketGlass platform, which brings together industry experts and influencers to provide high-quality, accurate insights. This unique platform allows us to gather comprehensive data and market perspectives, ensuring you receive the most reliable and detailed analysis available.Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie, Inc.
- Alfa Wassermann, Inc.
- Allergan PLC
- Amgen, Inc.
- Anterogen Co., Ltd.
- Ardelyx, Inc.
- Astellas Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Biogen, Inc.
- Celgene Corporation
- Cosmo Pharmaceuticals NV
- Drais Pharmaceuticals, Inc.
- Eisai Co., Ltd.
- Eli Lilly and Company
- Enlivex Therapeutics ltd.
- F. Hoffmann-La Roche AG
- Ferring Pharmaceuticals, Inc.
- FF Pharma
- Galapagos NV
- Gilead Sciences, Inc.
- GlaxoSmithKline, Inc.
- Hutchison MediPharma Limited
- Immune Pharmaceuticals, Inc.
- InDex Pharmaceuticals Holding AB
- Ironwood Pharmaceuticals, Inc.
- Johnson & Johnson
- Kissei Pharmaceutical Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- Lexicon Pharmaceuticals, Inc.
- Lipid Therapeutics GmbH
- Meda AB
- Merck & Co., Inc.
- Mesoblast Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Mochida Pharmaceutical Co., Ltd.
- Morphotek, Inc.
- Neovacs S.A.
- Nestle SA
- Norgine BV
- Novartis AG
- Pfizer, Inc.
- Procter & Gamble Company, The
- Qu Biologics Inc.
- RedHill Biopharma Ltd.
- Sterna Biologicals GmbH & Co. KG
- Synthetic Biologics, Inc.
- Takeda Pharmaceutical Co., Ltd.
- TiGenix NV
- Tillotts Pharma AG
- TopiVert Ltd.
- UCB SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 193 |
Published | August 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 69.9 Billion |
Forecasted Market Value ( USD | $ 99.2 Billion |
Compound Annual Growth Rate | 4.5% |
Regions Covered | Global |